Advancing Orthopedic Medicine
G-Ortho develops porcine-based biologic grafts that address the limitations of current tissue repair options, providing surgeons with consistent, readily available alternatives for ACL reconstruction, rotator cuff repair, and tendon reinforcement.
About G-Ortho Inc.
The demand for allograft tissue far exceeds supply, leaving surgeons and patients with limited options. G-Ortho Inc. provides a consistent, readily available alternative through our proprietary G-Process technology.
Our xenograft solutions offer surgeons an "off-the-shelf" biologic option that requires no change to their surgical procedure, while providing patients with safe, effective, and durable tissue repair.
25+
Years Clinical History
CE
Mark Approved
Extensive clinical validation with leading orthopedic institutions worldwide
Product Portfolio
A unique antigen stripping technology that humanizes intact animal tissue for human applications.
ACL Replacement
An "off-the-shelf" biologic ligament replacement for ACL reconstruction, revision ACL, multi-ligament knee rupture, and extra articular reconstruction procedures.
Tissue Matrix
A porcine dermal matrix uniquely treated that remodels into human tissue, providing biologic augmentation for soft tissue repair.
Bone Fixation
A porcine cortical bone fixation device that provides a complete biologic solution when used with G-Lig for ACL replacement.
Remove cells and fatty material from the tissue
Proprietary process removes alpha-gal antigens that trigger immune rejection
Proprietary process removes the primary non-gal antigens further humanizing the tissue
Modulates secondary immune response for optimal tissue integration
Below 2 mRads assures sterility
Xenograft remodels into human tissue over time
Our Technology
Lower species express specific carbohydrate epitopes called alpha-gal and non-gal antigens. Humans have evolved to produce antibodies that bind to these antigens, initiating rapid immune rejection.
The G-Process removes these antigens using proprietary enzyme-stripping technology, preventing the initial immune system attack and enabling xenograft tissue to successfully integrate with human tissue.
"The G-Process creates xenograft tissue that is young, healthy and strong which, 'ligamentizes' into normal appearing ACL tissue over time."
Clinical Evidence
Our technology platform is built on decades of clinical research and regulatory validation.
CE + FDA
CE Mark approval + US FDA wide clinical trial approval
30+
Years of US research and clinical history with gal-depleted tissue
85%
Follow-up rate in Level 1 randomized controlled trial
20+ yr
MRI follow up - first tissue to show remodeling from animal to human
Market Opportunity
The global ACL market represents a significant opportunity in one of the few remaining high-growth segments in orthopaedics.
High-growth, high-ASP market with substantial unmet need
Global injuries with over 1 million surgically treated
Rapid market expansion driven by increasing activity levels
Interested in learning more about G-Ortho's biologic solutions? We'd love to hear from you.
Contact Us